Skip to main content

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Publication ,  Journal Article
DiPersio, JF; Stadtmauer, EA; Nademanee, A; Micallef, INM; Stiff, PJ; Kaufman, JL; Maziarz, RT; Hosing, C; Früehauf, S; Horwitz, M; Cooper, D ...
Published in: Blood
June 4, 2009

This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in mobilizing hematopoietic stem cells in patients with multiple myeloma. Patients received G-CSF (10 microg/kg) subcutaneously daily for up to 8 days. Beginning on day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 microg/kg) or placebo subcutaneously. Starting on day 5, patients began daily apheresis for up to 4 days or until more than or equal to 6 x 10(6) CD34(+) cells/kg were collected. The primary endpoint was the percentage of patients who collected more than or equal to 6 x 10(6) CD34(+) cells/kg in less than or equal to 2 aphereses. A total of 106 of 148 (71.6%) patients in the plerixafor group and 53 of 154 (34.4%) patients in the placebo group met the primary endpoint (P < .001). A total of 54% of plerixafor-treated patients reached target after one apheresis, whereas 56% of the placebo-treated patients required 4 aphereses to reach target. The most common adverse events related to plerixafor were gastrointestinal disorders and injection site reactions. Plerixafor and G-CSF were well tolerated, and significantly more patients collected the optimal CD34(+) cell/kg target for transplantation earlier compared with G-CSF alone. This study is registered at www.clinicaltrials.gov as #NCT00103662.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

June 4, 2009

Volume

113

Issue

23

Start / End Page

5720 / 5726

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Heterocyclic Compounds
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cell Mobilization
  • Granulocyte Colony-Stimulating Factor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DiPersio, J. F., Stadtmauer, E. A., Nademanee, A., Micallef, I. N. M., Stiff, P. J., Kaufman, J. L., … 3102 Investigators, . (2009). Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 113(23), 5720–5726. https://doi.org/10.1182/blood-2008-08-174946
DiPersio, John F., Edward A. Stadtmauer, Auayporn Nademanee, Ivana N. M. Micallef, Patrick J. Stiff, Jonathan L. Kaufman, Richard T. Maziarz, et al. “Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.Blood 113, no. 23 (June 4, 2009): 5720–26. https://doi.org/10.1182/blood-2008-08-174946.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720–6.
DiPersio, John F., et al. “Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.Blood, vol. 113, no. 23, June 2009, pp. 5720–26. Pubmed, doi:10.1182/blood-2008-08-174946.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G, 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720–5726.

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

June 4, 2009

Volume

113

Issue

23

Start / End Page

5720 / 5726

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Heterocyclic Compounds
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cell Mobilization
  • Granulocyte Colony-Stimulating Factor